CHICAGO- and Nashville-based PE Shore Capital Partners announced the formation of Nashville-based PhaseWell Research, which owns dedicated clinical research sites and, as appropriate, embeds research within other curated sites in its still-expanding network.
Including this latest news, in the past year Shore has announced three platforms based in the Nashville area, the others being its Agentis Longevity platform and its Innovate 32 dental-services organization. VNC Shore coverage.
PhaseWell Research is the brand name or dba of SCP Clinical Research Intermediate Holdings LLC, which was registered in Tennessee three months ago. Related Delaware filings were posted in November 2024.
A month later, Nashville healthtech entrepreneur Carsten Bick became CEO.
Bick was previously director of operations for Murray, Utah-based R1 RCM, a revenue-cycle-oriented healthtech that more recently allied with Palantir. Earlier, he was SVP-Operations for Nashville's IVX Health (infusion and injection centers); and, VP for central and enterprise operations for Nashville-based NaviHealth (now Optum Home & Community, subsequent to its 2020 acquisition by UnitedHealth's OptumHealth).
In Shore's announcement earlier this month, PhaseWell said management is focused on "increasing participation in clinical trials by making research more accessible to patients across the country" in order to broaden trial participation that can accelerate medical innovation.
Shore VP Ankeet Patel said in Shore's Aug. 11 release, "Our strategy centers on partnering with outstanding operators, empowering top-tier leadership, assembling world-class boards, and providing the resources needed to grow. The clinical research site space is a natural fit for Shore, and we’ve consistently demonstrated our ability to scale complex multi-site healthcare and pharma services businesses."
In the same release, Bick said, in part, "We are driven by the urgent need to help solve growing challenges in this end of the value chain. Faster study start-up, improved patient recruitment, and higher-integrity data are required to ensure sponsor protocols are executed in an increasingly complex R&D environment. For our patient population, quality research represents access to potentially life-changing therapies not commercially available in the market today."
PhaseWell describes its network as supporting delivery of "comprehensive Phase I–IV clinical trial services across a broad range of therapeutic areas—including oncology, central nervous system (CNS), cardiovascular/metabolic, and dermatology. PhaseWell’s team of physicians and investigators are recognized industry leaders, known for their clinical expertise and operational excellence.
"By leveraging proven recruitment strategies and deep access to diverse patient populations through robust databases and strategic partnerships, PhaseWell has successfully completed more than 1,400 clinical trials and contributed to the approval of over 150 therapies," the company said. VNC
. last edited 29 August 2025 0520
